SEBA Bank (“SEBA”) successfully completes its Series C funding round, raising CHF 110 million through the issuance of participation certificates (non-voting shares). The financing round was co-led by a consortium of specialized blockchain and fintech investors,
Tags :Matthias Courvoisier
Occlutech Holding, a specialist provider of minimally invasive structural heart disease devices, addressing congenital heart defects, stroke prevention and heart failure, has successfully completed a private placement of Swedish Depositary Receipts (SDRs) worth SEK 450 million (
The first Swiss SPAC, VT5 Acquisition Company, successfully priced its initial public offering. The listing of the Class A Shares and Redeemable Warrants on
Zur Rose Group, e-commerce pharmacy and medical wholesalers, has concluded its accelerated bookbuilding (ABB) with the issuance of 650’000 new shares at an offer price of CHF 290 and gross proceeds of CHF 188.5 million. The shares were
Novartis has entered into an agreement to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a consideration of USD 20.7 billion. Novartis had acquired the stake between 2001 and 2003 for approximately USD 5
Varia US Properties, a Swiss-based real estate company investing exclusively in US multifamily housing with a focus on secondary and tertiary markets, has successful issued a CHF 50 million fixed-rate bond with a coupon of 2.875% and
Cosmo Pharmaceuticals and Cassiopea have entered into a transaction agreement under which Cosmo is launching a public exchange offer in Switzerland to acquire all of the publicly-held registered shares of Cassiopea. The public exchange offer
Baker McKenzie acted as legal advisor to Implantica in its primary issuance of shares, represented by Swedish Depository Receipts (“SDRs”), of SEK 600 million at a subscription price of SEK 122.20 per SDR. The subscription price was
Nice & Green, an independent Switzerland-based provider of innovative alternative financing solutions for small and mid-sized listed companies, announced a minority growth investment by Artemis Group, owned by Swiss entrepreneur Michael Pieper. The capital raised
Baker McKenzie advised Basilea Pharmaceutica on all legal aspects of the this PIPE transaction. The team consisted of Matthias Courvoisier (Partner, Capital Markets - pictured left), Philip Spoerlé (Senior Associate, Capital Markets - pictured right),
